Macter International 1HFY26 Profit Up 9% to Rs427 Million as Sales Jump 24%

Macter International, a mid-sized Pakistani drug maker, grew sales sharply in the first half of its financial year and lifted profit, though a heavier tax bill kept the bottom-line gain modest. The result shows a company expanding its top line and improving margins at the same time.

What the Macter International 1HFY26 results showed

Macter International reported net profit of Rs427.2 million for the half year ended December 31, 2025, up 9 percent from Rs392 million a year earlier. Revenue rose 24.2 percent to Rs6.11 billion from Rs4.92 billion. The quality of that growth was good. Cost of sales rose only 16.5 percent, slower than sales, so gross profit jumped 33.7 percent to Rs2.94 billion and the gross margin widened to 48.2 percent from 44.8 percent. Earnings per share rose to Rs9.32 from Rs8.56. The reason profit grew less than gross profit was tax. The income tax charge nearly doubled, rising about 87.5 percent year on year, which absorbed much of the operating gain.

Why it matters for pharma stocks

Pakistani drug makers have benefited from the deregulation of many medicine prices, which lets them pass on costs and improve margins rather than absorb them. Macter's gross margin moving above 48 percent fits that pattern, since it points to better pricing and cost control on the products it sells. Strong revenue growth of nearly a quarter suggests volumes are healthy as well, not just prices. The main drag is outside the company's hands, a higher tax burden that reflects the wider squeeze on listed firms from rising effective tax rates. Imported raw material costs and the rupee are the other swing factors for a manufacturer that buys active ingredients abroad.

Which stocks, and why

This is a direct result for Macter International, and the read is positive. Sales up 24 percent, gross profit up 34 percent and a wider margin together point to a strong operating performance, in line with the good run across listed pharma. The influence is medium because the gains are sustained and central to the business, while the heavier tax charge tempers the profit growth and shows part of the upside is leaking to the government rather than shareholders. The standing risk is the durability of drug price deregulation.

What to watch

Track volume growth alongside the margin gains, the cost of imported raw materials and the rupee, and the effective tax rate, since tax is what held back this half. Watch whether the company sustains a gross margin near 48 percent and whether the policy stance on drug pricing holds, as that has been the sector's main tailwind.